Literature DB >> 17846769

Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-alpha-methyl-tyrosine for SPECT imaging of gliomas.

Dirk Hellwig1, Bernd F M Romeike, Ralf Ketter, Jean R Moringlane, Carl-Martin Kirsch, Samuel Samnick.   

Abstract

OBJECTIVES: Radioactive amino-acids accumulate in gliomas even with an intact blood-brain-barrier. L-3-[(123)I]-iodo-alpha-methyl-tyrosine (IMT) is well established for SPECT imaging of gliomas. Recently, we introduced p-[(123)I]-iodo-L-phenylalanine (IPA) for the characterisation of brain lesions. This study compares both tracers in glioma patients.
METHODS: Eleven patients with gliomas (1 WHO grade 1, 5 grade 2, 1 grade 3, 2 grade 4 gliomas, 1 unconfirmed upgrading and 1 post-therapeutic non-neoplastic lesion) underwent SPECT imaging with IPA (early and delayed acquisitions at 30 min and 3 h) and IMT (early only). Maximum tumour-to-brain ratios (TBR) were calculated using region-of-interest analysis to assess uptake of IMT and IPA. Imaging results were compared to histopathological findings.
RESULTS: Early TBRs of IMT and IPA were strongly correlated (r = 0.828, p = 0.002). TBRs were higher for IMT than IPA (1.95+/-0.50 versus 1.79+/-0.42; p < 0.05), but independent from tumour cell density (p > 0.1). Visual interpretation by different observers was more concordant for IMT-SPECT than IPA-SPECT (kappa 1.0 versus 0.774). No differences in early TBRs were observed between low-grade and high-grade gliomas for IMT (1.97+/-0.53 versus 2.21+/-0.44, p > 0.5) or IPA (1.70+/-0.23 versus 2.21+/-0.56, p = 0.167) with a trend to higher TBRs in low-grade tumours for IMT (p = 0.093). In contrast to the known wash-out of IMT, we observed persistent accumulation of IPA in gliomas.
CONCLUSIONS: IPA shows lower TBRs than IMT, especially in low-grade tumours, so IMT should be preferred for the delineation of low-grade gliomas by SPECT imaging. Due to its prolonged retention, however, IPA remains promising for therapeutic use in gliomas after labelling with I-131.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846769     DOI: 10.1007/s00259-007-0514-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

1.  O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.

Authors:  Dirk Pauleit; Frank Floeth; Kurt Hamacher; Markus J Riemenschneider; Guido Reifenberger; Hans-Wilhelm Müller; Karl Zilles; Heinz H Coenen; Karl-Josef Langen
Journal:  Brain       Date:  2005-02-02       Impact factor: 13.501

2.  EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues.

Authors:  T Vander Borght; S Asenbaum; P Bartenstein; C Halldin; O Kapucu; K Van Laere; A Varrone; K Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

3.  Multimodality image registration by maximization of mutual information.

Authors:  F Maes; A Collignon; D Vandermeulen; G Marchal; P Suetens
Journal:  IEEE Trans Med Imaging       Date:  1997-04       Impact factor: 10.048

4.  Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.

Authors:  J B Bader; S Samnick; J R Moringlane; W Feiden; A Schaefer; S Kremp; C M Kirsch
Journal:  Eur J Nucl Med       Date:  1999-02

5.  Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT.

Authors:  Burkhard Riemann; Karsten Papke; Norbert Hoess; Torsten Kuwert; Matthias Weckesser; Peter Matheja; Hansdetlef Wassmann; Walter Heindel; Otmar Schober
Journal:  Radiology       Date:  2002-11       Impact factor: 11.105

6.  Iodine-123-alpha-methyl tyrosine in gliomas: correlation with cellular density and proliferative activity.

Authors:  T Kuwert; S Probst-Cousin; B Woesler; C Morgenroth; H Lerch; P Matheja; S Palkovic; M Schäfers; H Wassmann; F Gullotta; O Schober
Journal:  J Nucl Med       Date:  1997-10       Impact factor: 10.057

7.  Clinical value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up.

Authors:  Samuel Samnick; Jochen B Bader; Dirk Hellwig; Jean Richard Moringlane; Christof Alexander; Bernd F M Romeike; Wolfgang Feiden; Carl-Martin Kirsch
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

8.  Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas.

Authors:  W A Weber; S Dick; G Reidl; B Dzewas; R Busch; H J Feldmann; M Molls; C B Lumenta; M Schwaiger; A L Grosu
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

9.  123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study.

Authors:  Michail Plotkin; Julia Eisenacher; Harald Bruhn; Reinhard Wurm; Roger Michel; Florian Stockhammer; Annelie Feussner; Oliver Dudeck; Peter Wust; Roland Felix; Holger Amthauer
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

Review 10.  Imaging gliomas with positron emission tomography and single-photon emission computed tomography.

Authors:  François Bénard; Jonathan Romsa; Roland Hustinx
Journal:  Semin Nucl Med       Date:  2003-04       Impact factor: 4.446

View more
  7 in total

1.  An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Linda Grasfeder; Michael R Zalutsky; Bennett Chin
Journal:  Appl Radiat Isot       Date:  2011-05-19       Impact factor: 1.513

2.  Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Andrea Schaefer; Georgios Farmakis; Aleksandar Grgic; Jean R Moringlane; Wolf-Ingo Steudel; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-30       Impact factor: 9.236

3.  Radiosynthesis and biological evaluation of alpha-[F-18]fluoromethyl phenylalanine for brain tumor imaging.

Authors:  Chaofeng Huang; Liya Yuan; Keith M Rich; Jonathan McConathy
Journal:  Nucl Med Biol       Date:  2013-03-23       Impact factor: 2.408

4.  Synthesis and Biological Evaluation of (S)-Amino-2-methyl-4-[(76)Br]bromo-3-(E)-butenoic Acid (BrVAIB) for Brain Tumor Imaging.

Authors:  Jennifer L Burkemper; Chaofeng Huang; Aixiao Li; Liya Yuan; Keith Rich; Jonathan McConathy; Suzanne E Lapi
Journal:  J Med Chem       Date:  2015-10-20       Impact factor: 7.446

Review 5.  Progress on the diagnosis and evaluation of brain tumors.

Authors:  Huile Gao; Xinguo Jiang
Journal:  Cancer Imaging       Date:  2013-12-11       Impact factor: 3.909

6.  The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma.

Authors:  Eva Rainer; Hao Wang; Tatjana Traub-Weidinger; Georg Widhalm; Barbara Fueger; Jingling Chang; Zhaohui Zhu; Christine Marosi; Alexander Haug; Marcus Hacker; Shuren Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-30       Impact factor: 9.236

Review 7.  A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

Authors:  Julie Bolcaen; Janke Kleynhans; Shankari Nair; Jeroen Verhoeven; Ingeborg Goethals; Mike Sathekge; Charlot Vandevoorde; Thomas Ebenhan
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.